首页> Cancer chemotherapy and pharmacology> A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.

A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.

导出原文传递

翻译打印收藏纠错

第一作者： Hiromi,Kataoka

第一单位： Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.

作者： Hiromi,Kataoka ^[1] ; Yoshinori,Mori ^[2] ; Takaya,Shimura ^[1] ; Hirotada,Nishie ^[1] ; Makoto,Natsume ^[1] ; Hisato,Mochizuki ^[3] ; Yoshikazu,Hirata ^[3] ; Satoshi,Sobue ^[3] ; Takashi,Mizushima ^[4] ; Hitoshi,Sano ^[4] ; Yusuke,Mizuno ^[5] ; Makoto,Nakamura ^[5] ; Atsuyuki,Hirano ^[6] ; Kenji,Tsuchida ^[6] ; Kazunori,Adachi ^[6] ; Kyoji,Seno ^[6] ; Mika,Kitagawa ^[7] ; Takashi,Kawai ^[7] ; Takashi,Joh ^[1]

作者单位： Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan. ^[1] Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan. ysmori@med.nagoya-cu.ac.jp. ^[2] Department of Gastroenterology, Kasugai Municipal Hospital, 1-1-1 Takaki-cho, Kasugai, Aichi, 486-8510, Japan. ^[3] Gifu Prefectural Tajimi Hospital, 5-161, Maehata-cho, Tajimi, Gifu, 507-8522, Japan. ^[4] Toyokawa City Hospital, 23 Noji, Yahata-cho, Toyokawa, Aichi, 442-8561, Japan. ^[5] Nagoya City West Medical Center, 1-1-1 Hirate-cho, Kita-ku, Nagoya, Aichi, 462-8508, Japan. ^[6] Nagoya City East Medical Center, 1-2-23 Wakamizu, Chikusa-ku, Nagoya, Aichi, 464-8547, Japan. ^[7]

关键词 Advanced gastric cancer (AGC)Human epidermal growth factor receptor type 2 (HER2)Trastuzumab